Celldex completes enrollment in Phase 2 study of barzolvolimab

Celldex Therapeutics announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. “We are extremely grateful to the investigators and patients who supported this trial and are pleased that we were able to complete enrollment well ahead of schedule,” said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics. “CSU is an often serious and debilitating disease with significant impacts on patient quality of life, and there is a high unmet need for new treatment options. We believe barzolvolimab holds significant promise as a potential new treatment for patients with chronic urticarias and look forward to presenting topline data from the CSU study before the end of the year.”